The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer

Hepato-Gastroenterology

Volumn 57, Issue 99-100, 2010, Pages 640-645

  Aliustaoglu, Mehmet ^a   Bilici, Ahmet ^b   Seker, Mesut ^b   Dane, Faysal ^c   Gocun, Murat ^a   Konya, Volkan ^a   Ustaalioglu, Bala Basak Oven ^b   Gumus, Mahmut ^b  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Lymphocyte; Neutrophil; Neutrophil to lymphocyte ratio; Pancreatic carcinoma; Peripheral blood count; Platelet; Platelet to lymphocyte ratio; Prognosis

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTE COUNT;

ADULT; AGED; BLOOD PLATELETS; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPHILS; PANCREATIC NEOPLASMS; PLATELET COUNT; PROGNOSIS; SURVIVAL RATE;

EID: 77955541359     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer tatistics: CA Cancer J Clin. 2008; 58(2): 71-96.
2. Herrmann R, Jelic S: Pancreatic cancer. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Supplement 2): ii25-26.
3. Royal RE, Wolf RA, Crane CH. Pancreatic Cancer. In: Cancer. Principles and Practice of Oncology. DeVita VT, Helman S, Roseberg SA (eds). 8th ed. Lippincott Williams & Wilkins: Philadelphia, 2008, pp 1086-1124.
4. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer: Lancet 2004; 27: 1049-57.
5. Tsiotos GG, Farnell MB, Sarr MG. Are the results of pancreatectomy for pancreatic cancer improving? World J Surg 1999; 23: 913-9.
6. Eloubeidi MA, Desmond RA, Wilcox CM, Wilson RJ, Manchikalapati P, Fouad MM, Eltoum I, Vickers SM: Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg 2006; 192(3):322-9.
7. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6): 567-79.
8. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226 (3): 248-57.
9. Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, Mann CD, Berry DP: Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2007; 33(7): 892-7.
10. Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P: Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007; 11(3):350-6.
11. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237: 74-85.
12. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91(3):181-4.
13. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP: Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008; 34(1): 55-60.
14. Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP: Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg. 2008; 12(8): 1422-8.
15. Sasaki A, Kai S, Endo Y, Iwaki K, Uchida H, Tominaga M, Okunaga R, Shibata K, Ohta M, Kitano S: Prognostic value of preoperative peripheral blood monocyte count in patients with colorectal liver metastasis after liver resection. J Gastrointest Surg. 2007; 11(5): 596-602.
16. Dominguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernandez-Del Castillo C: Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg. 2008; 32(6): 1051-6.
17. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009; 58(1): 15-23.
18. Bartsch H, Nair J: Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev 2004; 28: 385-391.
19. Hussein MR, Ahmed RA: Analysis of the mononuclear inflammatory cell infiltrates in the non-tumorigenic, pretumorigenic and tumorigenic keratinocytic hyperproliferative lesions of the skin. Cancer Biol Ther 2005; 4: 819-821.
20. Wang W, Bergh A, Damber JE: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004; 61: 60-72.
21. Altinoz MA, Korkmaz R: NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004; 51: 239-247.
22. Jaiswal M, LaRusso NF, Gores GJ: Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001; 281: 626-634.
23. Biarc J, Nguyen IS, Pini A, Gosse F, Richert S, Thierse D, Van Dorsselaer A, Leize-Wagner E, Raul F, Klein JP, Scholler-Guinard M: Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis). Carcinogenesis. 2004; 25(8): 1477-84.
24. Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY: Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004; 10(23): 7965-71.
25. Ardies CM: Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2003; 2: 238-246.
26. Zahorec R: Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
27. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, Prasad KR: Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32(8): 1757-62.
28. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U: Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007; 20; 25(12): 1562-9.
29. Royston P, Reitz M, Atzpodien J: An approach to estimating prognosis using fractional polynomials in meta-static renal carcinoma. Br J Cancer 2006; 19; 94: 1785-8.
30. Negrier S, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C, Escudier B: Groupe Français d'Immunotherapie. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunotherapie. World J Urol. 2005; 23(3): 161-5.
31. Donskov F, von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 1997-2005.
32. Bruckner HW, Lavin PT, Plaxe SC, Storch JA, Livstone EM: Absolute granulocyte, lymphocyte, and moncyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach. JAMA. 1982; 19: 247(7): 1004-6.
33. Elias EG, Leuchten JM, Buda BS, Brown SD: Prognostic value of initial mononucleated cell percentages in patients with epidermoid carcinoma of the head and neck. Am J Surg 1986; 152: 487-90.
34. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 16; 348(3): 203-13.
35. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M: Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006; 32(1): 22-8.
36. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A: Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother. 2003; 26(5):394-402.
37. Blake-Mortimer JS, Sephton SE, Carlson RW, Stites D, Spiegel D: Cytotoxic T lymphocyte count and survival time in women with metastatic breast cancer. Breast J. 2004; 10(3): 195-9.
38. Sierki E, Wojtukiewicz MZ: Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108.
39. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guille F, Patard JJ: Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006; 175(3 Pt 1): 859-63.
40. Gogus C, Baltaci S, Filiz E, Elhan A, Bedük Y: Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004; 63(3): 447-50.
41. Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000; 78(2): 137-42.
42. Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY: The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol. 2004; 92(1): 211-4.
43. Tamussino KF, Gücer F, Reich O, Moser F, Petru E, Scholz HS: Pretreatment hemoglobin, platelet count, and prognosis in endometrial carcinoma. Int J Gynecol Cancer. 2001; 11(3): 236-40.
44. Pedersen LM, Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9: 1826-1830.
45. Aoe K, Hiraki A, Ueoka H, Kiura K, Tabata M, Tanaka M, Tanimoto M: Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration. 2004; 71(2): 170-3.
46. Brown KM, Domin C, Aranha GV, Yong S, Shoup M: Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg. 2005; 189(3):278-82.
47. Schwarz RE, Keny H: Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001; 48:1493-8.
48. Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, Kitajima M: Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology. 2004; 51(57): 847-53.
49. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009; 197(4): 466-72.